Robenacoxib (Onoxeb®) in veterinary practice: tolerability and safety in the treatment of pain syndromes in dogs and cats

The study evaluated the tolerability and safety of the non-steroidal anti-inflammatory drug (NSAID) robenacoxib (Onoxeb®) when administered orally at therapeutic (2 mg/kg) and double therapeutic (4 mg/kg) doses in healthy dogs (n=8) and cats (n=8) for 28 and 22 days, respectively. Monitoring of clinical status, body weight, and morphological and biochemical blood parameters did not reveal statistically significant or clinically important abnormalities that exceeded the physiological limits. In individual animals in the group that received the drug at a high dose, temporary and reversible gastrointestinal symptoms (salivation, softening of feces) were observed, which is consistent with the stated safety profile of the drug. The results confirm the good tolerability of robenacoxib and its safety for target animal species when used at recommended doses for an extended period.